Drug Profile
Adenyl cyclase gene therapy - Collateral Therapeutics
Alternative Names: Adenylyl cyclase gene therapy - Collateral TherapeuticsLatest Information Update: 26 Sep 2006
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Cardium Therapeutics; University of California, San Diego
- Class Gene therapies
- Mechanism of Action Adenylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure